AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1 – Yahoo Finance
AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1Yahoo Finance31, 2017 (GLOBE NEWSWIRE) — AveXis, Inc. (AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from … Continue reading
